Acute myeloid leukemia (AML) is the most common and most deadly type of leukemia in adults, affecting approximately 3 people per 100,000. AML is typically treated with a cocktail of chemotherapeutic drugs, most often involving the pharmaceutical agent cytosinearabinoside (Ara-C). Treatment with Ara-C will almost always cause remission in AML patients. However, developed resistance to Ara-C becomes a problem for many patients suffering from the disease, and many relapse within a few years of remission. We are using an in vitro system to model the Ara-C resistance in AML cell lines.
Additional contributors: Susan K. Rathe; David A. Largaespada (faculty mentor)
Funding for this project was provided by The Leukemia and Lymphoma Society (grant 7019-04).
Ellingson, Alexandra M..
Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.